Silexion Therapeutics Corp (SLXN): Submission of Matters to a Vote of Security Holders

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery

Silexion Therapeutics (NASDAQ: SLXN) reported Q2 2026 results and said its SIL204 program moved into active Phase 2/3 for locally advanced pancreatic cancer. The company received Germany’s BfArM CTA approval and initiated the trial at Tel Aviv Sourasky Medical Center in late July. It also reported preclinical immune-sensitization data and closed a public offering with about $2.5M gross proceeds. Q2 R&D was ~$2.2M and net loss ~$3.6M.

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel

Silexion Therapeutics (SLXN) priced a $2.5 million public offering of 3.85 million ordinary shares and Series E warrants at $0.65 per share, with warrants exercisable at $0.65 and expiring in five years. Net proceeds will fund its Phase 2/3 SIL204 trial and general purposes. SLXN fell 31% to $1.03.

Tel Aviv Sourasky Medical Center and Israeli biotech Silexion Therapeutics (Nasdaq: SLXN) announced a first-in-world clinical trial of SIL204, an siRNA therapy targeting KRAS mutations in pancreatic cancer. The study will enroll about 18 patients initially to assess safety, then expand, potentially to 166. SIL204 will be injected into tumors and combined with standard systemic treatment.

Silexion Therapeutics said Germany’s BfArM approved it to start a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, following a positive ethics opinion from the North Rhine Medical Association. The company also has Israel approval. Site activation is underway, with first patient dosing expected in the coming weeks.